Monopar Therapeutics Files 2024 10-K
Ticker: MNPR · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, stock-options
TL;DR
Monopar Therapeutics 2024 10-K filed: $14.3M assets, $6.1M cash, stock options detailed.
AI Summary
Monopar Therapeutics filed its 2024 10-K, reporting total assets of $14,338,403 as of December 31, 2024. The company had cash and cash equivalents of $6,102,560. The filing also details outstanding stock options, with 43,523 options vesting over time, and exercise prices ranging from $1.70 to $3.71 per share.
Why It Matters
This 10-K filing provides a comprehensive overview of Monopar Therapeutics' financial health and operational status as of the end of fiscal year 2024, crucial for investors assessing the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Monopar Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- $14.3B — Total Assets (As of December 31, 2024, indicating the company's overall financial resources.)
- $6.1B — Cash and Cash Equivalents (As of December 31, 2024, representing readily available funds for operations.)
- 43,523 — Stock Options Vesting (Details on employee stock options that are scheduled to vest, impacting potential dilution.)
Key Players & Entities
- Monopar Therapeutics (company) — Filer of the 10-K
- December 31, 2024 (date) — Reporting period end date
- $14,338,403 (dollar_amount) — Total assets as of December 31, 2024
- $6,102,560 (dollar_amount) — Cash and cash equivalents as of December 31, 2024
- 43,523 (number) — Number of stock options vesting
- $1.70 (dollar_amount) — Lowest exercise price for stock options
- $3.71 (dollar_amount) — Highest exercise price for stock options
FAQ
What were Monopar Therapeutics' total assets as of December 31, 2024?
Monopar Therapeutics reported total assets of $14,338,403 as of December 31, 2024.
How much cash and cash equivalents did Monopar Therapeutics have at the end of fiscal year 2024?
As of December 31, 2024, Monopar Therapeutics had $6,102,560 in cash and cash equivalents.
What is the range of exercise prices for Monopar Therapeutics' outstanding stock options?
The exercise prices for Monopar Therapeutics' outstanding stock options range from $1.70 to $3.71 per share.
How many stock options are set to vest for Monopar Therapeutics?
A total of 43,523 stock options are scheduled to vest for Monopar Therapeutics, with specific vesting schedules detailed in the filing.
What is the SIC code for Monopar Therapeutics?
Monopar Therapeutics is classified under SIC code 2834, which pertains to Pharmaceutical Preparations.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Monopar Therapeutics (MNPR).